Targeting non-alcoholic fatty liver disease through 11-βHSD1 inhibition

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 5, 2014, Pages 354-356

  Ratziu, Vlad ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b CENTRE DE RECHERCHE SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; GLITAZONE DERIVATIVE; LIVER PROTECTIVE AGENT; PLACEBO; RO 5093151; UNCLASSIFIED DRUG; FATTY ACID; GLUCOCORTICOID; OXIDOREDUCTASE INHIBITOR;

BODY FAT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FAT CONTENT; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIVER PROTECTION; NONALCOHOLIC FATTY LIVER; NOTE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT REDUCTION; DRUG MECHANISM; GLUCONEOGENESIS; HYPERINSULINEMIA; LIPOGENESIS; LIPOLYSIS; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; FEMALE; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; FEMALE; HUMANS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84899980130     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70028-2     Document Type: Note

References (10)

1. Cusi K Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012, 142:711-725. e6.
2. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675-1685.
3. Stefan N, Ramsauer M, Jordan P, et al. Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014, published online Feb 17. http://dx.doi.org/10.1016/S2213-8587(13)70170-0.
4. Gathercole LL, Lavery GG, Morgan SA, et al. 11beta-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. Endocr Rev 2013, 34:525-555.
5. Morton NM, Holmes MC, Fievet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001, 276:41293-41300.
6. Li G, Hernandez-Ono A, Crooke RM, Graham MJ, Ginsberg HN Effects of antisense-mediated inhibition of 11beta-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism. J Lipid Res 2011, 52:971-981.
7. Rosenstock J, Banarer S, Fonseca VA, et al. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010, 33:1516-1522.
8. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology 2008, 135:100-110.
9. Konopelska S, Kienitz T, Hughes B, et al. Hepatic 11beta-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis. Clin Endocrinol (Oxf) 2009, 70:554-560.
10. Westerbacka J, Yki-Jarvinen H, Vehkavaara S, et al. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 2003, 88:4924-4931.